Pulmonary function testing (PFT) is used to characterize non-infectious pulmonary complications after allogeneic BMT. Identifying high-risk patients could facilitate preventive or early therapeutic measures. The objectives of the study were first, to review available data on PFT changes after BMT and second, to validate a previously published predictive index for PFT obstruction in patients transplanted at one center. For the systematic review, frequency, severity and time course of PFT changes after BMT and for the validation study, retrospective cohort comparing predicted with observed PFT, and calculation of indices of predictive accuracy were summarized. The validation study involved 434 patients from Princess Margaret Hospital, Toronto, Canada, who received their first BMT between 1980 and 1997, survived for at least 6 months and had adequate PFT follow-up. The systematic review included 20 studies. After BMT, decreased diffusion and total lung capacity were common and partially reversible. Obstruction was less common. The validation study of a previously published index, performed in 434 patients, found a sensitivity and specificity of 48% and 68% for identifying patients who develop obstruction. We concluded that PFT changes after BMT are common. A published predictive index is not sufficiently accurate to identify high-risk patients for potential preventive or early therapeutic strategies. The lung is often a target organ for complications after allogeneic marrow transplantation (BMT), 1,2 with pulmonary complications including infection, neoplasia, and idiopathic and iatrogenic disorders such as pulmonary edema, diffuse alveolar hemorrhage and obliterative bronchiolitis (OB). In the latter process, bronchioles become progressively constricted and obliterated from intramural infiltration, fibrosis and scarring. After BMT, pulmonary function testing (PFT) can be useful to help diagnose complications, and in routine follow-up, as PFT abnormalities correlate with non-relapse mortality.
The lung is often a target organ for complications after allogeneic marrow transplantation (BMT), 1, 2 with pulmonary complications including infection, neoplasia, and idiopathic and iatrogenic disorders such as pulmonary edema, diffuse alveolar hemorrhage and obliterative bronchiolitis (OB). In the latter process, bronchioles become progressively constricted and obliterated from intramural infiltration, fibrosis and scarring. 1 After BMT, pulmonary function testing (PFT) can be useful to help diagnose complications, and in routine follow-up, as PFT abnormalities correlate with non-relapse mortality. 3 There are three main categories of PFT abnormalities. Obstructive defects occur when there is small airway closure or obstruction on expiration, leading to diminished forced expiratory volumes (one second forced expiratory volume -FEV1), classically with a preserved forced vital capacity (FVC), resulting in a decrease in FEV1/FVC ratio. In the BMT population, the prototypical cause of obstruction is OB. Its occurrence has been linked to chronic graft-versus-host disease (cGVHD), [4] [5] [6] [7] [8] [9] [10] [11] and its frequency has been estimated to range from 8 to 33%. 4, [6] [7] [8] [12] [13] [14] Although defined histologically, the diagnosis is most often presumptive, made based on signs and symptoms, radiographic changes and PFT showing obstruction, hyperinflation and gas trapping.
Restriction is a pattern of decreased lung volumes (TLC, best measured by body plethysmography), with a preserved FEV1/FVC ratio. Our group and others have identified a decrease in TLC post BMT which tends to improve over time, 3, 11, [15] [16] [17] with a reported incidence of up to 24%. 3 Many factors could contribute to restriction in this population, including thoracic radiation, cytotoxic chemotherapy, pulmonary edema, infectious or idiopathic interstitial pneumonia, and bronchiolitis obliterans organizing pneumonia. The final PFT derangement is one of diminished diffusion capacity for carbon monoxide (DCO). This is the most common abnormality, with a reported frequency of over 50%, 3, 5, [16] [17] [18] and tends to improve over time. 3, 5, 11, [16] [17] [18] Potential causes include many of the factors that contribute to restriction. Abnormalities of PFT post BMT have been shown to be prognostically important. 3 For patients with a drop of more than 15% from their pre-BMT TLC, a statistically significant increase in mortality has been reported, with a relative risk of 2.3. A moderate to severe impairment in DCO was associated with a trend toward increased mortality, as was the presence of any degree of obstruction. [5] [6] [7] [8] [9] [10] [11] The ability to identify patients at high risk for developing PFT abnormalities, caused by non-infectious post-BMT pulmonary complications, would permit the targeting of potential preventive strategies or surveillance and early intervention.
Given the importance of PFT changes after BMT, and the lack of a published systematic review, our objective was to review the available data on PFT changes after BMT, and assess whether sufficient data exist to predict which patients develop PFT derangements. We also sought to assess the accuracy of a predictive index for the development of post-BMT PFT obstruction developed by Clark et al 4 by applying it to a sample of BMT patients transplanted at our center.
Methods

Systematic review
To identify relevant studies, we searched the English language literature referenced in Medline from 1966 to October 2001 and Embase from 1980 to October 2001 as follows. The first set consisted of citations identified using 'bone marrow transplantation' as a subject heading or 'marrow transplant' as a truncated keyword to include 'transplant' and 'transplantation'. The second set was generated using 'respiratory function tests', 'spirometry', 'diffusion', 'forced expiratory flow rates', 'forced expiratory volume', 'vital capacity', 'plethysmography', 'pulmonary gas exchange', or 'lung volume measurements', as subject headings or keywords or 'pulmonary function' as a keyword. The sets were combined with an 'and' statement and all abstracts in the resulting set were reviewed. Studies were retrieved if they presented PFT results in patients both before and at least 3 months after BMT. Reference lists of review articles and retrieved studies were also assessed for relevant titles. Relevant studies were reviewed in full to obtain information on the frequency and risk factors for developing post-BMT PFT abnormalities. The frequency, magnitude and timing of effects of BMT on PFT were quantified using weighted averages from the selected studies. We calculated the overall fraction (95% confidence interval (CI)) of patients who developed obstruction, restriction or impaired diffusion. The magnitude and timing of changes in FEV1/FVC, TLC and DCO in entire study populations was also averaged. These data are presented as the maximal drop from pre-BMT levels, maximal recovery from nadir, and the timing, in months after BMT of the nadir and recovery. All averages were weighted by the number of study subjects.
Validation study
We evaluated the only predictive index we identified, developed by Clark et al. 4 It was derived using multiple linear regression, based on data collected in 218 patients with PFTs performed before and 12 months after BMT. The index estimates 12 month post-BMT FEV1/FVC ratio based on pre-BMT ratio, cGVHD, methotrexate GVH prophylaxis and age (Table 5 ). We applied this equation to a cohort of patients who received BMT at our center, and calculated the sensitivity, specificity, predictive values and likelihood ratios for predicting obstruction. We categorized our patients as to the presence of an obstructive complication post BMT based on an absolute decrease in FEV1/FVC ratio of at least 0.1 (eg a decrease from 0.8 to 0.7). Although a FEV1/FVC ratio of less than 0.7 is the only well-studied diagnostic PFT assessment for obstruction, 19 this is based on a single measurement. Since we had pre-and post-BMT measurements available, we reasoned that a clinically significant change in PFT would be a more accurate assessment. To our knowledge, the minimal clinically important difference in FEV1/FVC has not been well studied. We chose the value of 0.1 based on two sources. First, we surveyed all pulmonary faculty members at the University of Toronto, asking how they would define a clinically significant decrease in FEV1/FVC, suitable to identify new or worsening obstruction. The average of their responses was 0.1. Second, in the analogous situation in lung transplantation (OB is a major problem, and surrogate PFT markers are often used), the most recent international guidelines propose that a 10% fractional drop in FEV1/FVC ratio (eg a decrease from 0.8 to 0.72) from previous best is suggestive of possible OB. 20 Our somewhat more stringent definition was chosen based on similarity to the criterion proposed for lung transplantation, the results of our survey and simplicity.
We next used the published equation to calculate a predicted post-BMT FEV1/FVC ratio and compared this to the observed value. 'Predicted obstruction' was defined as the presence of a predicted ratio of at least 0.1 lower than the measured pre-BMT ratio. In testing the regression equation, we compared whether patients were observed to develop obstruction, vs their classification according to the published index. We tested the index in several ways. First, we calculated the diagnostic test characteristics on our patients at 12 months follow-up ('narrow horizon'), using the observed FEV1/FVC ratio at 12 months post BMT. We also calculated a correlation coefficient between observed and expected FEV1/FVC values for the 'narrow horizon' analysis. Next, to test the model's predictive utility for the development of obstruction at any time during the high-risk period, we included all patients who had pre-and at least one post-BMT PFT performed between 4 and 36 months after transplant. In this 'broad horizon' analysis, we used the lowest follow-up FEV1/FVC recorded within 36 months of BMT to determine whether a patient developed obstruction, and compared this to the 'predicted obstruction.' Sensitivity, specificity, predictive values and likelihood ratios were calculated twice -for narrow (12 month) and broad (4-36 month) time horizons. Differences between cohorts were assessed using chi-square (Yates corrected for twoby-two tables) or Fisher's exact tests where appropriate.
Receiver operating characteristic (ROC) curves for the narrow and broad horizon analyses were plotted. For the main analyses, a predicted decrease of at least 0.1 was the threshold used to define 'predicted obstruction'. We varied the threshold or definition of 'predicted obstruction' between extremes of 'predicted decreases,' to yield maximal sensitivities and specificities. CIs for area under ROC curves were calculated using the non-parametric method of Hanley and McNeil. 21 The validation cohort consisted of patients who received BMT at the Princess Margaret Hospital (PMH) / Ontario Cancer Institute, a 100 bed tertiary-care cancer hospital, part of the University Health Network in Toronto, Ontario, Canada. We included all patients who received their first BMT from 1980 to 1997, and survived for at least 6 months. PFT are routinely performed pre-BMT, at 6 and 12 months post BMT, and at yearly intervals thereafter. In addition to lung volume and DCO measurement, routine assessment includes flow rates (FEV1, FEV1/FVC), adequate to employ the published predictive index. The two laboratories that performed PFT over the study period have similar instrumentation, predictive formulae, and protocols.
Clinical data were collected from the patient record of the PMH, and PFT results were obtained from the original reports at the respective laboratories. Data abstraction was not blinded. Data were entered directly into an electronic database (Access 2000, Microsoft, Redmond, WA, USA) with subsequent assessment of data integrity performed by reviewing, for a second time, 10% of the primary sources and comparing results with the study database. Also, validity of certain variables obtained from clinicians' assessment notes (rather than original treatment or laboratory reports) were verified for 10% of patients by comparing information with that recorded in an independently and prospectively acquired database maintained by the BMT program. Error rates of greater than 5% for variables required to calculate a predicted FEV1/FVC and 1% for the determination of post-BMT FEV1/FVC ratio, would prompt iterative 10% rereviews of all records until similarly determined error rates were below this level. All analyses were performed using SAS version 8.0 (SAS Institute, Cary, NC, USA), Epi Info 2000 and The ROC Calculator version 5.0 (Centor and Keightley, Richmond, VA, USA). This study was approved by the Princess Margaret Hospital institutional ethics board.
Results
Systematic review
The search strategy yielded a list of 289 citations whose abstracts were reviewed. Twenty studies presented PFT results in patients both before and at least 3 months after BMT and were reviewed in full. [3] [4] [5] [6] [7] 11, 16, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] These reports provided information on up to 1786 allogeneic BMT patients. The exact number is unclear due to overlap in patient samples between studies, and incomplete description of numbers of patients with PFT data and allo-vs autoBMT. The latter problem inevitably leads to the inclusion of a relatively small but uncertain number of patients with autoBMT in the subsequent analysis. 3, 11, 29, 30 three studies had 100 or more patients, 4, 5, 16 and one study did not clearly state the number of patients with pre-and post-BMT PFTs. 3 Seven studies were limited to adults, 4, 7, 16, 25, 26, 30, 32 six studied only children, 6, 24, 27, 28, 31, 34 five studied adults and children, 3, 5, 22, 23, 33 and the remaining two did not specify patient ages. 11, 29 Conditioning regimens commonly included cyclophosphamide, busulfan and total body irradiation (TBI). Follow-up PFT was performed over a range of 3-156 months post BMT. Although not clearly stated in many studies, it appears that most were retrospective.
There was a tendency for all studied PFT parameters to deteriorate ( Table 2 ). The fraction of patients with PFT abnormalities is expressed as percent (95% CI). The most commonly observed abnormality post BMT was a decrease in DCO with partial recovery, observed in 83% (82.2, 84.4) of patients. Average absolute percent predicted changes in DCO were an 18% decrease by 6 months after transplant, and a 9% recovery by 35 months, based on 757 patients. Restriction was the next most common, seen in 35% (34.5, 35.7), and also generally improved over time. The average decrease in TLC was 16% predicted by 9 months, with a recovery of 12% by 32 months, based on 496 patients. Twenty-three % (22.5, 22.9) of subjects developed obstruction, which tended to be persistent. FEV1/FVC decreased an average of 3% by 22 months, with a recovery of approximately 1% by 32 months, based on 270 patients. Although the minimal clinically important change in FEV1/FVC has not, to our knowledge been studied, a change of 3% is undoubtedly insignificant at the level of the individual patient. Minimal clinically important differences in TLC and DCO have also not been studied. Most restrictive changes were subclinical, but the relatively uncommon obstructive changes, were accompanied by significant symptoms. [5] [6] [7] 33 Risk factors for the development of PFT abnormalities were identified in several studies, listed in Table 1 . Obstruction was associated with GVHD in 12 studies, [4] [5] [6] [7] 11, 16, 22, 26, 29, 30, 32, 33 increasing age at transplant in pediatric patients in two studies, 6, 31 and increasing HLA mismatch, 6 leukemia, 33 busulfan conditioning 30 and alveolar capillary permeability, 25 in one study each. Restriction was associated with GVHD in four studies, 16, 22, 23, 30 and TBI, 16 single fraction TBI, 11 infection, 23 busulfan conditioning, 30 CMV seropositivity, 24 increasing age among pediatric patients 31 and age less than 18 years overall, 23 in one study each. Impairments of diffusion were associated with GVHD in four studies, 5, 16, 22, 23 and TBI, 22 CMV seropositivity, 24 female sex, 34 infection, 23 smoking, 26 increasing age in pediatric patients, 31 age less than 18 overall, 23 T cell depletion 22 and chronic myelocytic leukemia 32 in one study each. GVHD was the most commonly identified risk factor, most often associated with obstruction, but also restriction and impaired diffusion.
Clark et al 4 performed a thorough analysis of risk factors for obstruction. They analyzed a subset of 506 allo-and autoBMT patients transplanted between 1977 and 1985 with follow-up PFT 12 months post BMT. Two hundred and eighteen patients had both pre-and 12 month post-BMT PFT. The authors screened 18 variables in univariate GVHD = graft-versus-host disease; PFT = pulmonary function test; Ara-C = cytosine arabinoside; CY = cyclophosphamide; TBI = total body irradiation; MePred = methylprednisolone; BU = busulfan; FVC = forced vital capacity; FEV1 = one-second forced expiratory volume; TLC = total lung capacity; DCO = diffusion capacity; MTX = methotrexate; CMV = cytomegalovirus; HLA = human leukocyte antigen; MUD = matched unrelated donor; RV = residual volume. Abnormalities defined as below fifth percentile for healthy age, sex, race and height-matched subjects; j Isolated impairment of diffusion; k Based on patient number at study initiation, estimates of nadir and recovery, include only studies with greater than one post-BMT observation.
analyses, and used statistically significant variables to model the FEV1/FVC 12 months after BMT with linear regression (Table 5) . They also evaluated risk factors associated with the development of obstruction, defined as an FEV1/FVC less than 70%. They identified independent and synergistic associations between cGVH and methotrexate use and the development of obstruction. The relative risk (RR) for cGVH alone was 4.6, and the corresponding value for methotrexate was 4.4. Although neither of these figures was statistically significant, when both risk factors were present, there was a statistically significant RR of 12.4 for the development of obstruction.
Validation study
From 1980 to 1997, 873 allogeneic BMT were performed at our center, and 593 patients survived for at least 6 months. Three hundred and thirty-five had PFT performed pre-BMT and 12 months post, and had adequate information to calculate a predicted FEV1/FVC ratio according to Clark et al. 4 Therefore, 335 patients were used to validate the 12-month predictive ability of the equation. For evaluation of the broad time horizon predictive ability, 434 patients had pre-and at least one 6-36 month post-BMT PFT and adequate information to calculate a predicted Bone Marrow Transplantation FEV1/FVC ratio. Regarding accuracy of data collection, rereview of patient records showed 2% of predictive characteristics data had been entered incorrectly. No inconsistency in classification of patients according to FEV1/FVC was found. The observed error rates were within our pre-specified acceptable limits.
Characteristics of patients in Clark's study, our 12-month validation cohort, and our broad horizon validation cohort are presented in Table 3 . There was significant overlap between the 12 month and broad horizon validation cohorts. Our cohorts had significantly less cGVHD and obstruction (FEV1/FVCϽ0.7) at 12 months. Using our definition of obstruction (absolute decrease in FEV1/FVC of at least 0.1), 22% of patients in Clark's cohort (12 months), 5% in our narrow horizon cohort (12 months), and 11% in our broad horizon cohort (4-36 months) developed obstruction (Table 3 ). Both validation cohorts had a statistically lower rate of obstruction than that of the derivation cohort (P Ͻ 0.0001 for each), and the broad horizon group had a higher rate of obstruction than the narrow horizon group (P = 0.005). Figure 1 shows a plot of predicted vs observed FEV1/FVC at 12 months (Pearson correlation coefficient 0.53, P = 0.005). Predictive test characteristics in the validation cohorts are presented in Table 4 . The equation cor- Table 3 Characteristics of patients in derivation and validation cohorts 4 sample size of 281 includes all patients with 12-month post-BMT PFTs, pre-BMT studies were available for 218. b Patients transplanted at our center with pre-and 12 months post-BMT PFTs, and clinical information to calculate a predicted FEV1/FVC ratio. c Patients transplanted at our center with PFT pre-and at least one follow-up study between 6 and 36 months post-BMT. FEV1/FVC = one second forced expiratory volume/forced vital capacity; TLC = total lung capacity; HLA = human leukocyte antigen; GVHD = graftversus-host disease. rectly classified 64% and 66% of patients in the 'narrow' and 'broad' horizon analyses, respectively. The sensitivity was 25% in the narrow horizon analysis and 48% in the broad horizon analysis. The specificity was similar in both analyses (67% and 68%). For the narrow horizon analysis, the positive likelihood ratio is less than 1, and the negative likelihood ratio is greater than 1, counterintuitive results due to the equation's poor predictive ability. The area under the ROC curve for the 12 month analysis was 0.55 (95% CI 0.43-0.67), implying the equation is no better than chance (curve not shown). The area under the broad horizon analysis curve was 0.63 (95% CI 0.55-0.72), implying slightly better than chance performance ( Figure  2 ). Visual inspection did not suggest a useful diagnostic threshold. The analyses were repeated using a slightly different endpoint definition, OB defined as a 10% decrease in FEV1/FVC ratio (eg 0.8 to 0.72) rather than an absolute decrease of 0.1 (eg 0.8 to 0.7), resulting in no significant difference. 
Discussion
Although extensive data describing pulmonary manifestations of BMT have been published, the body of work has several shortcomings, and our review is therefore limited. Clinically apparent (vs none or subclinical) chronic GVHD (P = 0.04) chronic GVHD (P Ͻ 0.0001); replaced in final model by interaction term Interstitial pneumonia within 100 days after NS Not studied transplant FEV1/FVC = ratio of one second forced expiratory volume to forced vital capacity; GVHD = graft-versus-host disease; HLA = human leukocyte antigen; NS = not statistically significant at P = 0.05 level; TLC = total lung capacity. 
Predictive equation of Clark et al
Bone Marrow Transplantation
Data regarding the magnitude of changes in specific PFT measurements and the fraction of patients developing specific derangements are often incompletely reported (Table  2) , requiring estimates to be based on relatively small numbers of patients. Sample sizes are generally small, and larger studies generally provide only a single, early post-BMT assessment. Aggregate estimates are also difficult to interpret, given the differences between studies. Investigators may employ different treatment protocols and definitions of PFT abnormalities, follow-up times are variable, the number of patients at each follow-up is often not provided, and observations on allogeneic vs autologous transplant recipients are sometimes not distinguished. Because we were unable to completely separate data from auto-and alloBMT patients, our review includes data from a small, but uncertain number of autoBMT patients. Although the proportion cannot be calculated exactly, it is estimated to be less than 5%, and likely does not significantly alter our findings.
There may have been bias in selecting patients for follow-up PFT in the reviewed studies. Survivor bias may occur because PFT cannot be obtained on patients who have died, potentially from pulmonary causes, and may not be performed on patients with very severe complicationsboth leading to an underestimate of the frequency and severity of PFT abnormalities. Loss to follow-up may occur, given the large catchment areas of transplant programs and follow-up at distant centers. If sicker patients tend to return to the transplant center for follow-up and treatment, one would overestimate rates of complications. If PFT was performed non-systematically, oversampling patients with pulmonary symptoms, our figures overestimate the frequency and severity of PFT abnormalities.
Another important limitation reflects the rapid evolution of BMT protocols. Of the 20 studies we reviewed, 11 contained no patients transplanted after 1990 (up to 1305 patients). Of the nine more recent studies (up to 481 patients) which provided transplant dates, all included patients transplanted in the 1980s, and none described patients transplanted after 1995. Our estimates may therefore be less applicable to current BMT patients.
In validating the regression equation presented by Clark et al, we found suboptimal predictive characteristics. The index correctly classified 64-66% of patients based on whether they developed an obstructive complication. We feel that it is most important to avoid misclassification of high-risk patients, and suggest that sensitivity is a more important characteristic. The sensitivity of the tested index was 25% for the narrow horizon (12 month) analysis, and 48% for the broad horizon (4-36 month) analysis. Regardless of analysis, the low sensitivity suggests this index is not clinically useful.
The results of our validation assessment are not unexpected. The equation was developed to predict post-BMT FEV1/FVC, but was tested in identifying patients with an absolute decrease of at least 0.10 from pre-BMT levels. There are also important differences between the derivation and validation populations. Currently, there is increased use of cyclosporine -associated with a significant decrease in cGVHD and OB. 15 Ganciclovir prophylaxis or early treatment for patients at risk for CMV disease, has nearly eliminated the 20% risk of mortality from CMV, 18 but may lead to long-term pulmonary compromise in patients who survive CMV pneumonia. There is increased use of busulfan, with its well-known pulmonary toxicities, which may be related to both obstruction and restriction. 30, 35 Matched unrelated donor transplants have become common practice and are associated with far higher rates of GVHD, mortality, and possibly pulmonary complications. 5 There are also several methodologic issues in the derivation of the index. Of 506 patients transplanted, only 218 had pre-and 12 month post-BMT PFTs. Although the baseline characteristics of patients with and without follow-up were generally similar, in the group without follow-up, twice as many received single dose TBI (25% vs 12%, P = 0.0003), and had lower rates of cGVHD (50% vs 66%, P = 0.0004) and extensive cGVHD (32% vs 59%, P Ͻ 0.0001). This suggests differential follow-up, the introduction of bias and reduction of generalizability. The relatively short follow-up of 1 year is also problematic. Patients in our cohort continued to develop obstruction over time and others have shown this to be important until about 30-36 months post BMT. 7 Finally, cigarette smoking was associated with a lower FEV1/FVC in univariate analysis, but could not be tested in the multivariable model due to missing data.
In summary, the large body of information regarding PFT changes after BMT has several important limitations, providing an incomplete understanding of this problem. Given the poor performance of the only published predictive instrument, we are unable to confidently identify patients who will develop obstruction after BMT, an important manifestation of OB. Currently, cGVHD is the main factor understood to relate to the development of OB, but it is an imperfect predictor. An improved method of identifying patients at high risk for developing obstruction and OB would permit the assessment of strategies of prevention or early intervention in this potentially devastating complication of BMT.
